NFKB1 and inflammatory bowel disease: Another example is the NF-κB signaling pathway, which is the major proinflammatory pathway in IMs and is considered a potential therapeutic target, but it can also promote the survival and proliferation of damaged IECs, thereby complicating the development of IBD-related therapies.